Cromoglicate
Clinical data | |
---|---|
Routes of administration | topical: oral, nasal spray, inhaled, eye drops |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 1% |
Elimination half-life | 1.3 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C23H16O11 |
Molar mass | 468.367 g/mol |
WikiDoc Resources for Cromoglicate |
Articles |
---|
Most recent articles on Cromoglicate Most cited articles on Cromoglicate |
Media |
Powerpoint slides on Cromoglicate |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Cromoglicate at Clinical Trials.gov Clinical Trials on Cromoglicate at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Cromoglicate
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Cromoglicate Discussion groups on Cromoglicate Patient Handouts on Cromoglicate Directions to Hospitals Treating Cromoglicate Risk calculators and risk factors for Cromoglicate
|
Healthcare Provider Resources |
Causes & Risk Factors for Cromoglicate |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cromoglicate (INN) (also referred to as cromolyn (USAN) or cromoglycate (former BAN)) is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.
Uses
It is available as a nasal spray (Rynacrom®(UK), Nasalcrom®) to treat allergic rhinitis, as an inhaler (Intal®) for preventive management of asthma, as eye drops (Opticrom® and Optrex Allergy® (UK), Crolom®) for allergic conjunctivitis, or in an oral form (Gastrocrom®) to treat mastocytosis, dermatographic urticaria and ulcerative colitis.
Sodium cromoglicate has also been shown to reduce symptoms of food allergies, including some cases of chronic migraines.
Mechanism of action
The underlying mechanism of action is not fully understood; for while cromoglicate stabilizes mast cells, this mechanism is probably not why it works in asthma. Pharmaceutical companies have produced 20 related compounds that are equally or more potent at stabilising mast cells and none of them have shown any anti-asthmatic effect. It is more likely that these work by inhibiting the response of sensory C fibres to the irritant capsacin, inhibiting local axon reflexes involved in asthma, and may inhibit the release of preformed T cell cytokines and mediators involved in asthma. (see review by Garland, 1991)
Allergic reactions
Allegic reactions may include severe rash internally and externally.
It is known to somewhat inhibit chloride channels (37% +/- 7%) [1] and thus may inhibit the:
- exaggerated neuronal reflexes triggered by stimulation of irritant receptors on sensory nerve endings (e.g. exercise-induced asthma)
- release of preformed cytokines from several type of inflammatory cells (T cells, eosinophils) in allergen-induced asthma
Note: Another chemical (NPPB (5-nitro-2(3-phenyl) propylamino-benzoic acid)) was shown, in the same study, to be a more effective chloride channel blocker.
Finally it may act by inhibiting calcium influx.
Cromoglicate is classified as a chromone.
References
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
Template:Asthma and copd rx
Template:SIB
- Pages with script errors
- Pages with citations using unsupported parameters
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Mast cell stabilizers
- Pulmonology
- Drug